Unresectable, previously untreated RAS/BRAF wt mCRC pts, were randomized to a control arm (A) receiving FOLFIRI/PANI continuously until progression or to the experimental arm (B), receiving 8 cycles of the same regimen followed by a treatment free interval. This lasted untill progressive disease...
背景:IMPROVE是一项随机、非对照、多中心、2期研究,旨在评估FOLFIRI+ panitumumab(FOLFIRI/PANI)持续用药直至疾病进展(PD)或间歇用药在不可切除初治RAS/BRAF野生型(WT)转移性结直肠癌(mCRC)患者中的疗效和安全性。间歇组接受8周期治疗,之...
f四tuximab, line treatment in KRAS wt,metastatic colorectal cancer: a pilot phase II cetuximab plus irinotecan,and panitumurnab for third and 缸rther Iin白 trial [J). Br) Cancer,2012, 107(12): 1932-1937. 。f treatment for KRAS wild-type patients with metastatic ∞10rectal 7. Tournig...
(2012). Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line pani- tumumab plus FOLFIRI treatment in a single-arm phase II study. BioMed Central Cancer, 12, 438.Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, ...
He was treated by the following chemotherapies [FOLFOX+CET, FOLFIRI+BEV, FOLFIRI+PANI] and ALF was introduced in 4th line. 3 courses of FOLFIRI+AFL were performed but the tumors were increased (PD). Conclusion Only Case1 showed tumor regression. But the other 3 cases those were treated by...
Combining bevacizumab and pani- tumumab with irinotecan,5 -fluorouraeil, and leucovorin( FOLFI- RI) as second - line treatment in patients with metastatic colorec- tal caneer[ J]. Med 0neol,2014,31 (6):976.Hong-LiangLiang, Ai-PingHu, Sen-LinLi, Ji-YongLiu. (2014) Combining ...
Randomized Phase III study of panitunmumah with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer [J]. JClin Oncol, 2010, 28(31) :4706 -4713....